Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03176394 · ClinicalTrials.gov registry record · NA

Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)

A NA study, sponsored by Next Science TM.

Terminated
Registry status
NA
Development phase
15
Enrollment target

NCT03176394 is a NA study that was terminated before completion, run by Next Science TM. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03176394, a NA study, was terminated before completion, sponsored by Next Science TM.

TERMINATED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated catheters. Urine and/or catheter DNA analysis will be obtained at catheter insertion, 2, 5, 7 and 14 days after catheterization.

Interventions

  • DEVICE BLASTX Gel
  • DEVICE McKesson Jelly

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2017-05-24
Est. Completion 2019-10-18
Phase NA

Sponsor

Next Science TM

7 total trials

What the Registry Record Tells You About NCT03176394

The ClinicalTrials.gov registry entry for NCT03176394 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Next Science TM, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which BLASTX Gel is the first listed.

NCT03176394 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03176394 about?

NCT03176394 is a clinical study titled "Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)". This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated catheters. Urine and/or catheter DNA analysis will be obtained at catheter inse...

What is the current status of trial NCT03176394?

This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2017-05-24. Estimated completion is 2019-10-18.

What interventions are being tested in trial NCT03176394?

The interventions under investigation include: BLASTX Gel (DEVICE), McKesson Jelly (DEVICE).

Who is sponsoring clinical trial NCT03176394?

This trial is sponsored by Next Science TM, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.